docs2imageIcon
dark theme
hamburger menu
Chart & Data
Search a stock ticker below to get started.
Search
ABCL - $8.57
AbCellera Biologics Inc.
1day
1w
1m
3m
6m
1yr
5yr
Yearly revenue growth: 0.0%
Yearly profit growth: 0.0%
Balance sheet (assets & liabs)
Institutional holders
Owner Share amount
Capital Research & Management Co.... 19,821,407
Allianz Global Investors U.S. LLC 11,437,050
Baker Bros. Advisors LP 10,450,180
SB Management Ltd. (AE) 9,817,190
Capital Research & Management Co.... 7,109,889
Harvard Management Co., Inc. 4,105,095
Guardian Capital Advisors LP 3,836,414
Baillie Gifford & Co. 3,573,908
Credit Suisse Securities (USA) LL... 2,802,411
Credit Suisse Asset Management (S... 2,500,000
AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Shareholder breakdown
general public
institutions
insiders